UK group Alltracel Pharmaceuticals says that its Czech Republic-based subsidiary Nanopeutics has entered into technology development partnership with Bristol-Myers Squibb group ConvaTec to develop wound care products.

ConvaTec, a manufacturer of ostomy and wound care products, has been working with Alltracel since 2006 under a development agreement for professional wound care and will also provide funding for the new partnership, while Alltracel will carry out certain laboratory testing and analysis work.

If the deal is successful, the groups may then enter into an exclusive royalty-bearing license and supply agreement, but further details were not disclosed.

Important market
Commenting on the alliance, Alltracel’s Chief Executive Tony Richardson said: “The professional wound care area is an important market for us and we are happy to be collaborating with a partner of ConvaTec’s caliber and heritage. Alltracel’s Nanospider technology affords many possibilities in this sector and seeks to improve product performance and assist in the treatment of many patients.”

Nanospider is a unique technology enabling the production nanofiber textiles on an industrical scale, invented and patented at The Technical University of Liberec, Czech Republic.